A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy

Background: To identify the maximum tolerated dose (MTD) of hyperthermic intraperitoneal cisplatin at 43°C among gynecological cancer patients. Methods: In this Phase I dose-finding trial, Bayesian optimal interval (BOIN) design was used. We sought to explore the MTD with a target dose-limiting toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Chui-ying, Li, Hui, Wu, Miao-fang, Liu, Chang-hao, Lu, Huai-wu, Lin, Zhong-qiu, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991782/
https://www.ncbi.nlm.nih.gov/pubmed/33777754
http://dx.doi.org/10.3389/fonc.2021.616264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991782/
https://www.ncbi.nlm.nih.gov/pubmed/33777754
http://dx.doi.org/10.3389/fonc.2021.616264

Ejemplares similares